While Class IC agents such as FLEC and RPROP are contraindicated in ischemia or heart failure due to their Na+ channel blocking properties [41], targeting RyR2 with agents such as carvedilol that exhibit open channel RyR2 block and hence use-dependence against Ca2+ waves appears a promising new paradigm for finding better anti-antiarrhythmic medicines [44]. The gene discussed is RYR2; the disease is heart failure.